The Immunosuppressive Tumor Microenvironment: Cellular and Metabolic Mechanisms of Immune Evasion and Emerging Therapeutic Strategies
Cancers · 17.11.2026 · 18 (22) · 3678
DOI: 10.3390/cancers18223678 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 17.11.2026. Verfasst von Constantin N. Baxevanis und 4 weiteren Autor:innen. Die Arbeit nennt 194 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The tumor microenvironment (TME) is a dynamic ecosystem that actively shapes cancer progression, therapeutic resistance, and immune escape. It comprises malignant cells, stromal and endothelial cells, extracellular matrix components, and infiltrating immune populations with both pro- and anti-tumor functions. While immune surveillance can eliminate transformed cells early in tumorigenesis, established malignancies undergo immunological and metabolic reprogramming that enables immune evasion and a durable suppressive niche, defined by accumulation of regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), tumor-associated neutrophils (TANs), regulatory B cells (Bregs) and tolerogenic dendritic cells (DCs). These populations inhibit cytotoxic T lymphocytes and natural killer cells via inhibitory cytokines, checkpoint engagement, metabolic competition, nutrient depletion, and immunosuppressive metabolites. Beyond classical regulatory signaling, metabolic remodeling is a central driver of immune suppression. Enhanced glycolysis and mitochondrial reprogramming in cancer cells cause nutrient depletion, hypoxia, and acidification, impairing immune-cell differentiation and function. Suppressive populations adapt by preferentially using oxidative phosphorylation, fatty acid oxidation, amino acid metabolism, and tumor-derived metabolites such as lactate, adenosine, and kynurenine, actively reinforcing immunosuppression. Lactate also signals to drive regulatory immune-cell differentiation, while tryptophan catabolism and adenosine signaling act as metabolic immune checkpoints that suppress effector lymphocytes. This review synthesizes the cellular and metabolic architecture of the immunosuppressive TME, highlighting bidirectional interactions between metabolic stress and immune dysfunction that drive tumor progression and therapy resistance, and discusses emerging therapeutic strategies targeting immunometabolic pathways, including reprogramming of suppressive populations and combination approaches pairing metabolic interventions with checkpoint blockade and adoptive cellular therapies.
Zitieren
APA
Baxevanis, C. N., Paschou, M. A., Angelis, N. V., Gritzapis, A. D., & Tsitsilonis, O. E. (2026). The Immunosuppressive Tumor Microenvironment: Cellular and Metabolic Mechanisms of Immune Evasion and Emerging Therapeutic Strategies. Cancers, 18(22), 3678. https://doi.org/10.3390/cancers18223678
Vancouver
Baxevanis CN, Paschou MA, Angelis NV, Gritzapis AD, Tsitsilonis OE. The Immunosuppressive Tumor Microenvironment: Cellular and Metabolic Mechanisms of Immune Evasion and Emerging Therapeutic Strategies. Cancers. 2026;18(22):3678. doi:10.3390/cancers18223678
BibTeX
@article{Baxevanis2026,
author = {Baxevanis, Constantin N. and Paschou, Maria A. and Angelis, Nikolaos V. and Gritzapis, Angelos D. and Tsitsilonis, Ourania E.},
title = {The Immunosuppressive Tumor Microenvironment: Cellular and Metabolic Mechanisms of Immune Evasion and Emerging Therapeutic Strategies},
journal = {Cancers},
year = {2026},
volume = {18},
number = {22},
pages = {3678},
doi = {10.3390/cancers18223678}
}
EUVIMED